Prevalence of Smear Negative Pulmonary Tuberculosis (SNPT) according to score and history of previous tuberculosis, Lima, Peru, 2005–2008.

<p>Prevalence of Smear Negative Pulmonary Tuberculosis (SNPT) according to score and history of previous tuberculosis, Lima, Peru, 2005–2008.</p

Sociodemographic, clinical and radiological variables in smear negative patients with and without pulmonary tuberculosis. Lima, Peru, 2005–2008.

<p>Values in parenthesis are percentages unless otherwise indicated.</p><p>†Results available for 408 patients who accepted voluntary counselling and testing.</p><p>*Based on Fisher exact test.</p><p>PTB  =  Pulmonary tuberculosis.</p

Comparison of ROC curves for the score in patients without (blue) and with (red) previous history tuberculosis.

<p>Comparison of ROC curves for the score in patients without (blue) and with (red) previous history tuberculosis.</p

Proportion of patients with smear negative pulmonary tuberculosis by score values in subjects without and with previous history of tuberculosis.

<p>Proportion of patients with smear negative pulmonary tuberculosis by score values in subjects without and with previous history of tuberculosis.</p

Adjusted Odds Ratios for predictive variables included in the evaluated score [17] for smear negative pulmonary tuberculosis. Lima, Peru, 2005–2008.

<p>*Not-entered in the model since the only two cases with miliary infiltrate and no previous history of TB had a final diagnosis of pulmonary tuberculosis.</p

Type of research and approval process for studies submitted 2006–2008.

a<p>In most instances this means one cycle of resubmission; in a few cases, there were two cycles of resubmission.</p>b<p>Studies that were not submitted to ethics review prior to implementation cannot be approved after the fact. However, the ERB has agreed to provide advice on ethical issues prior to publication.</p

DST patterns in patients with no reported risk factors for MDR-TB: rates and confidence intervals.

<p>Legend: Mono resistant: resistance to a single drug out of the four tested; Poly resistant: resistance to at least two drugs not involving the combination of isoniazid and rifampicin; Only MDR: resistance to isoniazid and rifampicin only; MDR plus: resistance to isoniazid, rifampicin and another drug.</p

Patient enrolment and drug resistance results.

<p>Legend: DST = Drug susceptibility test; Drug resistant = any drug resistance, including MDR; MDR = multidrug resistant.</p

Characteristics and MDR status of patients without known risk factors.

<p>*Patient states having been in contact with a person with active TB who is alive and whose episode of TB was not report to be MDR TB.</p><p>**To calculate this odds ratio (OR), 0·5 was added to each value, and the standard formulae for OR, confidence intervals and p-value were applied.</p

Drug susceptibility testing results before the start (T0), after 3 months (T3), and at the end of treatment (T8) for patients remaining culture positive at the end of a full treatment course with comparison of RFLP results at T0 and T8.

<p>Number of patients  = 43.</p><p>RFLP, Restriction Fragment Length Polymorphism; H, Isoniazid; R, Rifampicin; E, Ethambutol; S, Streptomycin; n/a  =  not available.</p><p>* T0 and T3 isolates identical; T3 and T8 isolates different.</p><p>§ Both RFLP profiles were unique.</p><p>° Intermediate isolate (T3) showed different RFLP.</p><p>** RFLP at T8 not available, but RFLP patterns at T0 and T3 were different.</p